Ranbaxy Laboratories Ltd., a unit of Japan's Daiichi Sankyo, has stopped production of its generic version of cholesterol-lowering drug Lipitor as the company investigates what caused tiny glass particles to appear in some bottles, triggering a large recall earlier this month. Ranbaxy, holds more than 40% of the U.S. market for atorvastatin prescriptions.
In January, the U.S. Justice Department entered a consent decree against Ranbaxy, alleging flaws with its manufacturing practices and quality controls at several plants but not at those producing its atorvastatin line.
In January, the U.S. Justice Department entered a consent decree against Ranbaxy, alleging flaws with its manufacturing practices and quality controls at several plants but not at those producing its atorvastatin line.